Latest News & Features
Americas
Pharmaceutical pay-for-delay deals worth less than around $10 million are unlikely to be challenged by the authorities in US courts, according to a speaker at the 2016 AIPPI World Congress in Milan. 20 September 2016
Biotechnology
In a session moderated by Dominic Adair of Bristows, panellists at the 2016 AIPPI World Congress in Milan yesterday discussed biosimilars substitution and interchangeability. 20 September 2016
Big Pharma
Sweden-based pharmaceutical research company BioInvent International has been granted additional patent protection for its BI-505 immune oncology programme for myeloma. 19 September 2016
Americas
A patent counsel at Eli Lilly has blasted the US Supreme Court for being lazy in its approach to assessing the patentability of gene-based sequencing. 19 September 2016
Big Pharma
Brexit does not mean Brexit—it means “total chaos”, said one IP lawyer speaking at the 2016 AIPPI World Congress in Milan today. 19 September 2016
Big Pharma
The Association of the British Pharmaceutical Industry has welcomed the Department of Health’s new £816 million investment in health research, stating that it is “a signal of the government’s commitment to invest in innovation”. 16 September 2016
Americas
The US Federal Trade Commission has approved a final order that Teva’s acquisition of Allergan’s generic pharmaceutical business for $40.5 billion would be anticompetitive. 16 September 2016
Big Pharma
Ahead of the Life Sciences IP Summit 2016 from October 20 to 21 at the Hilton London Paddington Hotel, Sarah Porch of C5 previews the main talking points, including Brexit and the UPC. 16 September 2016
Biotechnology
Pharmaceutical company AbbVie has had its application to strike out a patent case filed against it by Fujifilm Kyowa Kirin Biologics dismissed. 15 September 2016
Americas
Pharmaceutical company Allergan is set to acquire clinical-stage biotechnology company Vitae Pharmaceuticals for $639 million. 15 September 2016